Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Apellis Pharmaceuticals, Inc. (NASDAQ: APLS).

Full DD Report for APLS

You must become a subscriber to view this report.


Recent News from (NASDAQ: APLS)

Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Macro matters: Traders are back to focusing on economic reports after no major deve...
Source: SeekingAlpha
Date: May, 05 2018 08:33
Apellis Pharmaceuticals beats by $0.88
Apellis Pharmaceuticals (NASDAQ: APLS ): Q1 EPS of -$0.43 beats by $0.88 . Cash and cash equivalents of $152.93M Press Release More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: April, 30 2018 17:01
Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
- APL-2 in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) On Track to Advance into Phase 3 Trials in 2H18 - - Cash Position of $152.9 Million at Quarter-End; April 2018 Public Offering Raised Additional $131.3 Million in Net Proceeds To Support Advancing APL-2 I...
Source: GlobeNewswire
Date: April, 30 2018 16:00
Alexion Clears A Path For 2nd Generation PNH Drug
Recently, Alexion Pharmaceuticals ( ALXN ) announced positive results from another phase 3 study for its second generation version of Soliris, known as ALXN1210. This study is good news for the company, because the trial showed that patients can be switched from soliris to ALXN1210 witho...
Source: SeekingAlpha
Date: April, 30 2018 04:36
Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today ann...
Source: GlobeNewswire
Date: April, 23 2018 18:20
Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock
CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today ann...
Source: GlobeNewswire
Date: April, 18 2018 21:25
Midday Gainers / Losers (04/17/2018)
Gainers: CNET +42% . WMLP +21% . CIFS +21% . CLXT +20% . IIN +19% . NVLN +15% . IFON +15% . DPW +14% . CHEK +14% . GTHX +14% . More news on: ChinaNet Online Holdings, Inc., Westmoreland Resource Partners, LP, China Internet Nationwide Financial Services Inc...
Source: SeekingAlpha
Date: April, 17 2018 12:40
Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today ann...
Source: GlobeNewswire
Date: April, 16 2018 17:11
Midday Gainers / Losers (04/16/2018)
Gainers: OSN +26% . ERI +17% . SHOS +13% . APLS +13% . HEAR +13% . FTD +12% . FSCT +12% . OASM +11% . PMTS +11% . BXC +11% . More news on: Ossen Innovation Co., Ltd., Eldorado Resorts, Inc., Sears Hometown and Outlet Stores, Inc., Stocks on the move, , ...
Source: SeekingAlpha
Date: April, 16 2018 12:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1723.7024.5024.57523.52286,006

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1518,52246,07040.2040Short
2018-08-145,09144,00911.5681Cover
2018-08-134,80315,49031.0071Cover
2018-08-1012,54527,11046.2744Short
2018-08-0917,94631,59156.8073Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APLS.


About Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Logo for Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: APLS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: April, 19 2018
      Registration of up to an additional 20% of securities for any offering registered on an S-1
      Filing Type: S-1MEFFiling Source: edgar
      Filing Date: April, 18 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 18 2018
      General form for registration of securities under the Securities Act of 1933
      Filing Type: S-1Filing Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 19 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: APLS)

      Daily Technical Chart for (NASDAQ: APLS)


      Stay tuned for daily updates and more on (NASDAQ: APLS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: APLS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APLS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of APLS and does not buy, sell, or trade any shares of APLS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/